Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

Statistical analysis of dental plaque removal data provides the quantitative foundation for verifying the cleaning efficacy of toothbrushes, toothpastes, mouth rinses, and interdental devices. By applying validated plaque indices, controlled clinical or laboratory protocols, and rigorous inferential statistics, manufacturers can substantiate performance claims with objective, reproducible evidence. This article explains how plaque removal studies are designed, which metrics are measured, and how the resulting datasets are statistically analyzed in accordance with ISO standards and accredited third-party laboratory practice.

Technical Overview

Dental plaque is a structured biofilm that accumulates on tooth surfaces and represents the primary etiological factor in caries and periodontal disease. Evaluating how effectively an oral care product removes or suppresses this biofilm requires more than a single observation; it demands a systematically designed study, standardized measurement instruments, and a defensible statistical analysis pipeline. Plaque removal data are typically collected as ordinal index scores or as percentage-area measurements from disclosed plaque, and the resulting distributions are often non-normal, skewed, and subject to examiner variability. For this reason, accredited third-party laboratories apply formal hypothesis-testing frameworks, power calculations, and assumption diagnostics before any efficacy conclusion is drawn.

The statistical evaluation of plaque removal serves three purposes: quantifying the magnitude of plaque reduction relative to baseline, demonstrating superiority or equivalence against a comparator product, and estimating the uncertainty of these estimates through confidence intervals. International standards such as ISO 20126 for manual toothbrushes and ISO 20127 for powered toothbrushes define laboratory test conditions, while clinical investigations are generally structured in alignment with Good Clinical Practice principles and ISO 14155 requirements for medical device studies.

Testing Samples

Manual Toothbrushes

Manual toothbrushes are evaluated under ISO 20126 laboratory protocols, in which specimen substrates are coated with plaque-simulating artificial biofilm and brushed under controlled force, stroke count, and duration. Data from repeated brushing cycles across multiple specimen replicates are compiled to characterize cleaning performance over the brush head surface and edge zones.

Powered Toothbrushes

Electric and sonic toothbrushes are tested in accordance with ISO 20127, with brushing machines that standardize contact pressure and motion while the device operates at its nominal settings. Multi-cycle datasets allow statistical comparison of cleaning patterns between brushing modes and between test and reference devices.

Dentifrices and Toothpastes

Toothpaste formulations are assessed for their contribution to plaque removal and plaque regrowth inhibition, typically in randomized clinical trials governed by ISO 11609 general requirements for dentifrices. Antiplaque agents such as stannous fluoride, zinc salts, and essential oil systems are compared against placebo or fluoride-only controls.

Mouth Rinses

Oral rinses are evaluated for whole-mouth plaque reduction and regrowth suppression using supervised rinse regimens and timed plaque scoring sessions. Test design follows the general safety and performance expectations set out in ISO 16408 for oral rinses.

Interdental Cleaning Devices

Dental floss, interdental brushes, and oral irrigators are analyzed for interproximal plaque removal, where index scoring is restricted to approximal surfaces or complemented by planimetric imaging of interproximal regions.

Testing Items

Core measured endpoints in plaque removal studies include the following:

  • Whole-mouth plaque index scores, most commonly the Turesky Modification of the Quigley-Hein Index (0–5 ordinal scale) or the Silness and Löe Plaque Index (0–3 scale)
  • The O'Leary Plaque Index, expressing the percentage of tooth surfaces retaining disclosed plaque
  • Rustogi Modification of the Navy Plaque Index, which resolves nine scored zones per buccal surface for regional analysis
  • Planimetric area measurements: percentage of tooth surface area covered by disclosed plaque, quantified from standardized digital photographs
  • Regional subset scores for interproximal, gingival margin, buccal, and lingual zones
  • Plaque regrowth curves measured at 24-hour, 48-hour, and 72-hour checkpoints in experimental gingivitis models
  • Baseline-to-post-brushing deltas and percentage plaque reduction values

Testing Methods

Clinical Study Design

Clinical assessments follow randomized, examiner-blinded designs, either in parallel-arm or crossover configuration. Participants receive a dental prophylaxis, abstain from oral hygiene during a designated plaque accumulation period, and are then scored before and after a single supervised brushing or rinse event. A neutral or red disclosing agent visualizes plaque, and calibrated examiners record index scores under standardized lighting. Crossover designs, in which each subject tests all products with adequate washout intervals, reduce inter-subject variance and are statistically more efficient for paired comparisons.

Laboratory and In Vitro Methods

ISO 20126 and ISO 20127 laboratory methods use brushing machines operating on substrates such as bovine enamel, hydroxyapatite discs, or PMMA plates coated with plaque-simulating layers. Fluorescent or dye-stained artificial biofilm is quantified before and after brushing using image analysis, generating continuous percentage-removal data suitable for parametric treatment. Each specimen acts as its own control, producing paired observations.

Statistical Analysis Workflow

The analysis pipeline applied by accredited third-party laboratories typically proceeds through defined stages:

  • Sample size determination: a priori power analysis targeting 80–90% power at a two-sided significance level of 0.05, based on the expected between-product difference and published variance estimates for the selected index
  • Descriptive statistics: mean, standard deviation, median, interquartile range, and 95% confidence intervals for baseline, post-treatment, and delta scores
  • Assumption verification: Shapiro–Wilk or Kolmogorov–Smirnov testing for normality, Levene's test for homogeneity of variance, and inspection of residual distributions
  • Parametric inference: paired t-tests for baseline-versus-post comparisons, independent t-tests for between-group comparisons in parallel designs, and ANCOVA with baseline score as covariate for adjusted treatment effects
  • Non-parametric alternatives: Wilcoxon signed-rank test for paired ordinal data, Mann–Whitney U test for independent groups, and Friedman or Kruskal–Wallis tests for multi-period or multi-product designs
  • Repeated measures analysis: repeated-measures ANOVA or linear mixed-effects models for longitudinal regrowth studies, with subject as a random effect to account for within-subject correlation
  • Multiple comparison control: Bonferroni adjustment or Tukey HSD when several products or time points are tested simultaneously
  • Effect size reporting: Cohen's d, eta squared, or rank-biserial correlation to convey practical significance beyond p-values

Both intention-to-treat and per-protocol populations are analyzed in clinical studies, with predefined handling of dropouts and missing data. All statistical procedures are documented in a statistical analysis plan prepared before database lock to preserve data integrity.

Applications

Statistically validated plaque removal data support a wide range of commercial and regulatory objectives:

  • Substantiation of marketing claims such as "removes significantly more plaque" or "reduces plaque by a defined percentage versus a manual brush"
  • Verification of compliance with ISO 20126 and ISO 20127 performance expectations during product development and pre-market evaluation
  • Competitive benchmarking against reference or predecessor products under identical controlled conditions
  • Optimization of bristle tuft patterns, filament stiffness, brush head geometry, and powered brushing modes during R&D iteration
  • Support for regulatory dossiers, retailer listing requirements, and professional dental association acceptance submissions
  • Peer-reviewed publication of efficacy findings with transparent methodology and reproducible statistical reporting

FAQ

How is percentage plaque reduction calculated?

Percentage reduction is computed as the difference between baseline and post-treatment scores divided by the baseline score, multiplied by 100. Group-level statistics are calculated from per-subject reduction values rather than from group means alone, and confidence intervals are reported for the mean reduction.

Which plaque index should be used?

The Turesky Modification of the Quigley-Hein Index is the most widely used instrument in product efficacy trials because its 0–5 scale offers sensitivity to subtle changes and is well validated for interproximal staining. The O'Leary Index and planimetric area measurements are preferred when a simple, intuitive percentage output is required.

When should non-parametric tests be applied?

Ordinal index data, small sample sizes, or failed normality testing indicate the use of Wilcoxon signed-rank, Mann–Whitney U, or Friedman procedures. Many laboratories apply both parametric and non-parametric analyses to confirm that conclusions are robust to the choice of method.

Can laboratory brushing machine results replace clinical trials?

Laboratory data under ISO 20126 and ISO 20127 provide highly controlled, reproducible comparisons suitable for design screening and standards compliance, but they cannot capture gingival response, user technique, or compliance effects. Clinical confirmation remains necessary for consumer-facing efficacy claims.

What sample size is typically required?

Crossover toothbrush studies commonly enroll 30 to 60 evaluable subjects, while parallel-arm toothpaste trials frequently require larger cohorts of 80 or more participants depending on the expected effect size. Formal a priori power analysis is always performed to justify the final number.